PIK3CA and colorectal carcinoma: Moreover, we conducted a phase II clinical trial of a combination of CB-839 and capecitabine, an oral prodrug of 5-FU, in patients with metastatic PIK3CA-mutant CRC who were refractory to prior fluoropyrimidine-based chemotherapy.